ClinicalTrials.gg
RecruitingNCT05958706Updated Feb 19, 2026

Mitochondrial Substrate Utilization in the Diabetic Human Heart

An observational study in Heart Failure, Type2diabetes and Insulin Resistance, sponsored by Heinrich-Heine University, Duesseldorf. Recruiting at 1 site in Germany. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Heinrich-Heine University, Duesseldorf · Observational

How we know

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
20 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 600 studies in Heart Failure with a site in Germany — 105 open to participants now, 136 under way, 19 of them phase 3. Heart Failure · Germany.

Planned enrollment
75th of 212
500 · median 286
Started
2021
with 18 others
Observational
212 of 600
47 open now
Primary completion
2030-06
later than 124 of 135 live
Registered
495th of 600
by date

Among the 600 studies in Heart Failure with a site in Germany, this one is the 75th largest by planned enrollment of the 212 observational ones that give a count, is one of 19 that started in 2021, is one of 212 observational ones, reaches primary completion later than 124 of the 135 other live ones, and was the 495th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

105 of the 600 studies in Heart Failure with a site in Germany are open now. Recruiting first, the newest first:

100 more — sign in →

All 105 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 20 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 600 studies in Heart Failure with a site in Germany, or all of them as a file.
02

Study summary

Diabetes can lead to heart failure independently, but the underlying causes remain incompletely understood. The main aim of this study is to identify differential regulation of mitochondrial substrate utilization and complex activity in heart failure and type 2 diabetes mellitus (T2DM). For this, we will conduct a prospective, observational study to examine myocardial mitochondrial oxidative function and related metabolic parameters, gene expression, histological markers, and inflammation in cardiac tissue from patients with heart failure or patients after heart transplantation. We will further assess cardiac function using cardiac magnetic resonance imaging with and without stress protocols and magnetic resonance spectroscopy. Glycemic control/T2DM will be characterized by oral glucose tolerance tests. The results of this project will help to better understand the cellular mechanisms of the development of diabetic cardiomyopathy and contribute to the development of early diagnostic, as well as therapeutic approaches for the prevention and treatment of diabetic cardiomyopathy.

Read the detailed description

Insulin resistance, ectopic lipid accumulation in the liver, and plasma concentrations of free fatty acids are independent predictors of cardiac mortality, the primary cause of death in patients with type 2 diabetes mellitus (T2DM). T2DM predisposes to the development of heart failure independently of other risk factors. Ventricular dysfunction in diabetic patients independent of coronary artery disease or arterial hypertension is termed diabetic cardiomyopathy. Studies suggest that myocardial mitochondrial dysfunction, as well as accumulation of lipids and other metabolites, oxidative stress, and altered insulin signaling, play a significant role in the pathogenesis of diabetic cardiomyopathy. Thus, we also found evidence of impaired mitochondrial function in hyperglycemia and insulin resistance in previous analyses. Nevertheless, it remains unclear, among other things, at which point of mitochondrial metabolism the shown impairments originate, whether the availability of different substrates may influence these effects, what is the temporal sequence of pathomechanistic events, and what are the effect modifiers for the influence of T2DM on the myocardium.

The goal of the present work is to more precisely characterize the underlying pathomechanisms to answer these questions. The focus will be on respirometric analysis of human myocardial tissue samples established by our preliminary work. In previously published studies, we were able to establish its use for the first time in catheter-guided endomyocardial biopsies. By studying further heart failure and heart transplant patients, we will analyze the importance of myocardial mitochondrial function as a prognostic marker of further disease progression and, using larger power, investigate the influence of different effect modifiers.

The results of this project will help to better understand the cellular mechanisms of the development of diabetic cardiomyopathy and contribute to the development of early diagnostic, as well as therapeutic approaches for the prevention and treatment of diabetic cardiomyopathy.

Hypotheses:

  1. the reduced mitochondrial oxidative capacity of myocardial mitochondria in T2DM is complex- and substrate-specific.
  2. within patients with heart failure of unclear etiology and indication for myocardial biopsy, there are mitochondrial profiles with different clinical courses and outcomes.
  3. in T2DM, myocardial oxidative capacity is also longitudinally impaired in heart transplant patients and this impairment is associated with worse clinical outcome.

Objectives:

  1. identify specific targets for therapeutic strategies against diabetic cardiomyopathy: work program (WP) 1.
  2. characterization of myocardial mitochondrial function and its relevance to clinical phenotypes in heart failure: WP 2.
  3. investigation of T2DM as a longitudinal predictor of worse mitochondrial and clinical cardiac function in heart transplant patients: WP 3.

WP1:

The aim is to identify altered respiratory chain subcomponents and metabolic pathways associated with the development of manifest diabetic cardiomyopathy in T2DM. For this purpose, patients with and without T2DM (according to the criteria of the "American Diabetes Association" (ADA)) who have an indication for endomyocardial biopsy on clinical grounds will be included. A matched comparison between patients with and without T2DM will provide evidence of diagnostic and therapeutic targets for diabetic cardiomyopathy in newly diagnosed heart failure (with and without left ventricular ejection fraction limitation).

Patients:

  • Group 1: Patients with manifest heart failure (NYHA II-IV) with clinical indication to perform myocardial biopsy and T2DM according to the "American Diabetes Association" (ADA) criteria, HbA1c \< 9.0%, with/without therapy (insulin, oral/parenteral antidiabetic drugs).
  • Group 2: Patients with manifest heart failure (NYHA II-IV) with clinical indication to perform myocardial biopsy without T2DM.

WP2:

The aim is to characterize myocardial mitochondrial function and its relevance for clinical phenotypes in heart failure. For this purpose, patients with terminal heart failure from the heart failure program of the Department of Cardiology, Pneumology and Angiology of the University Hospital Düsseldorf who are scheduled for implantation of a left ventricular assist device (LVAD) or are undergoing heart transplantation will be included.

All study examinations of myocardial tissue are performed in an area of the left ventricular apex obtained during surgery (LVAD implantation or cardiac harvest), which is not further clinically analyzed or preserved and which therefore no longer has any direct benefit for the patients.

Patients:

  • Group 1: Patients with terminal heart failure and diagnosed T2DM according to the "American Diabetes Association" (ADA) criteria 18, HbA1c \< 9.0%, with/without therapy (insulin, oral/parenteral antidiabetic drugs).
  • Group 2: Patients with terminal heart failure (NYHA IV) without T2DM.

WP3:

The aim is to investigate T2DM as a longitudinal predictor of impaired mitochondrial and clinical cardiac function in heart transplant patients. For this purpose, patients who are included in the heart transplantation follow-up program of the University Hospital Düsseldorf and have the indication for endomyocardial biopsy within this program will be included. Routine myocardial biopsy is necessary in these patients to detect subclinical graft rejection early, as it is associated with increased mortality. Biopsies occur multiple times in the first year after transplantation, and in subsequent years (if there is no evidence of rejection), the goal is to monitor annually.

Patients:

  • Group 1: Patients after heart transplantation with diagnosed T2DM according to the "American Diabetes Association" (ADA) criteria 18, HbA1c \< 9.0%, with/without therapy (insulin, oral/parenteral antidiabetic drugs).
  • Group 2: Patients after heart transplantation without T2DM.
03

Conditions studied

  • Heart Failure
  • Type2diabetes
  • Insulin Resistance
  • Mitochondrial Diseases
  • Diabetic Cardiomyopathies

Keywords

  • mitochondrial function
  • respirometry
  • heart failure
  • type 2 diabetes mellitus
  • insulin resistance
  • mitochondrial disease
  • diabetic cardiomyopathy
04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with heart failure with or without T2DM undergoing endomyocardial biopsy for clinical reasons (WP1), patients with terminal heart failure with or without T2DM undergoing left ventricular assist device surgery or heart transplantation (WP2), and patients after heart transplantation with and without T2DM undergoing endomyocardial biopsy for clinical reasons (post-transplant surveillance).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 20 and ≤ 85 years
  • Male and female patients with manifest heart failure ( II-IV) and clinical indication for myocardial or after transplantation and clinical indication for myocardial biopsy with or without type II diabetes mellitus or terminal (NYHA IV) heart failure with or without type II diabetes mellitus.
  • Written

Exclusion criteria

Exclusion Criteria:

  • Acute infectious diseases within the last 2 weeks before the examination
  • diseases or acute immunocompromising diseases (leukocytes \< 5000/μl)
  • Pregnancy
  • Use of alcohol or drugs (addiction), psychiatric diseases
  • Suspected or manifest AIDS (); or C.
  • Liver disease not attributed to the presence of nonalcoholic fatty liver hepatitis or congestive hepatopathy in heart failure
  • Malignant cancer
  • Lack of capacity to give or lack of consent to participate in the study
  • For MRI study with drug stress: to the use of regadenoson, specifically: a) to the active ingredient or any of the other ingredients mentioned. b) Second- or third-degree atrioventricular (AV) block or sinus node dysfunction, unless these patients have a functioning pacemaker. c) Unstable angina that has not been stabilized with medication. d) Severe hypotension. e) Decompensated stages of heart failure.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • patients with manifest heart failure

    patients with manifest heart failure and T2DM or patients with manifest heart failure without T2DM

  • patients with terminal heart failure

    patients with terminal heart failure and T2DM or patients with terminal heart failure without T2DM

  • patients after heart transplantation

    patients after heart transplantation and T2DM or patients after heart transplantation without T2DM

06

What researchers measure

Primary outcomes

  1. Substrate-specific JVO2 of ventricular myocardial mitochondrial oxidative capacity

    measured in (pmol/s\*mg)

    Time frame: at time of the endomyocardial biopsy procedure

Secondary outcomes

  1. Markers of cardiac function and structure

    measured by cardiac magnet resonance tomography

    Time frame: 1 day before or after endomyocardial biopsy

  2. Markers of cardiac function

    measured by echocardiography

    Time frame: 1 day before or after endomyocardial biopsy

  3. Cardiac substrate utilization

    measured by cardiac magnet resonance spectroscopy (MRS)

    Time frame: 1 day before or after endomyocardial biopsy

  4. Patterns in the myocardial transcriptome and systemic metabolome

    Time frame: at time of the endomyocardial biopsy procedure

  5. non-fatal myocardial infarction

    Survival and clinical outcomes after study index visit (inclusion)

    Time frame: up to 5 years (follow-up in clinical routine)

  6. all-cause mortality

    Survival and clinical outcomes after study index visit (inclusion)

    Time frame: up to 5 years (follow-up in clinical routine)

  7. allograft rejection

    Survival and clinical outcomes after study index visit (inclusion)

    Time frame: up to 5 years (follow-up in clinical routine)

  8. hospitalization for heart failure

    Survival and clinical outcomes after study index visit (inclusion)

    Time frame: up to 5 years (follow-up in clinical routine)

  9. non-fatal stroke

    Survival and clinical outcomes after study index visit (inclusion)

    Time frame: up to 5 years (follow-up in clinical routine)

  10. Longitudinal Substrate-specific JVO2

    measured with sequential biopsies

    Time frame: variable, up to 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Jun 2030, 102 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 102 months is above that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2023
First posted
Jul 25, 2023
StartActual
Dec 1, 2021
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2035
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05958706
Responsible party
Sponsor
First posted
Jul 25, 2023
Start date
Dec 1, 2021
Primary completion
Jun 2030 (estimated)
Completion
Jun 2035 (estimated)
Last update
Feb 19, 2026

Study contacts

Elric Zweck, MD
Contact
elric.zweck@med.uni-duesseldorf.de
+492118118800
Amin Polzin, MD
Contact
amin.polzin@med.uni-duesseldorf.de
+49211811800
Malte Kelm, Prof.
study chair · Clinic for Cardiology, Pneumology and Angiology at University Hospital Düsseldorf
Elric Zweck, MD
principal investigator · Clinic for Cardiology, Pneumology and Angiology at University Hospital Düsseldorf

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion